Trial reportAJNR. American journal of neuroradiology2016
Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials.
Trial report in AJNR. American journal of neuroradiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Spinal metastasis: diagnosis, management and follow-up.The British journal of radiology · 2019Pooled it
- Stereotactic Body Radiotherapy for Spinal Metastases: What are the Risks and How Do We Minimize Them?Spine · 2016Pooled it
- Radiological response assessment after stereotactic body radiotherapy for spine metastases using magnetic resonance imaging: a systematic review.Physics and imaging in radiation oncology · 2025Review
- Heterogeneity of study endpoints in stereotactic body radiation therapy studies for bone metastases: A systematic review.Journal of radiosurgery and SBRT · 2025Article
- Advanced Radiotherapy Technologies in Spine Tumors: What the Surgeon Needs to Know.Global spine journal · 2025Article
- Review
- Article
- Stereotactic body radiation therapy for spinal metastases: A new standard of care.Neuro-oncology · 2024Review
- Practice and principles of stereotactic body radiation therapy for spine and non-spine bone metastases.Clinical and translational radiation oncology · 2024Article
- Multidisciplinary management of spinal metastases: what the radiologist needs to know.The British journal of radiology · 2022Review
- Review
- Review
- Response assessment after stereotactic body radiation therapy for spine and non-spine bone metastases: results from a single institutional study.Radiation oncology (London, England) · 2022Article
- Article
- [Single dose of 24 Gy or 3-fraction SBRT regimen in the treatment of oligometastatic cancer? : A phase III multi-center trial].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
- How Can Imaging Help the Radiation Oncologist in Multiple Myeloma Treatment.Medicina (Kaunas, Lithuania) · 2020Review
- Changes in Volume and Density Parameters Measured on Computed Tomography Images Following Stereotactic Body Radiation Therapy of Nonspine Bone Metastases.Technology in cancer research & treatment · 2019Article
- Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview.Frontiers in oncology · 2019Review
- Society of Skeletal Radiology 2016 Annual Meeting Summary.Skeletal radiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
background and purposeOsseous pseudoprogression on MR imaging can mimic true progression in lesions treated with spine stereotactic radiosurgery. Our aim was to describe the prevalence and time course of osseous pseudoprogression to assist radiologists in the assessment of patients after spine stereotactic radiosurgery. MATERIALS AND
methodsA secondary analysis of 2 prospective trials was performed. MRIs before and after spine stereotactic radiosurgery were assessed for response. "Osseous pseudoprogression" was defined as transient growth in signal abnormality centered at the lesion with a sustained decline on follow-up MR imaging that was not attributable to chemotherapy.
resultsFrom the initial set of 223 patients, 37 lesions in 36 patients met the inclusion criteria and were selected for secondary analysis. Five of the 37 lesions (14%) demonstrated osseous pseudoprogression, and 9 demonstrated progressive disease. There was a significant association between single-fraction therapy and the development of osseous pseudoprogression (P = .01), and there was a significant difference in osseous pseudoprogression-free survival between single- and multifraction regimens (P = .005). In lesions demonstrating osseous pseudoprogression, time-to-peak size occurred between 9.7 and 24.4 weeks after spine stereotactic radiosurgery (mean, 13.9 weeks; 95% CI, 8.6-19.1 weeks). The peak lesion size was between 4 and 10 mm larger than baseline. Most lesions returned to baseline size between 23 and 52.4 weeks following spine stereotactic radiosurgery.
conclusionsProgression on MR imaging performed between 3 and 6 months following spine stereotactic radiosurgery should be treated with caution because osseous pseudoprogression may be seen in more than one-third of these lesions. Single-fraction spine stereotactic radiosurgery may be associated with osseous pseudoprogression. The possibility of osseous pseudoprogression should be incorporated into the prospective criteria for assessment of local control following spine stereotactic radiosurgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.